Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
about
Glucose Metabolism in T Cells and Monocytes: New Perspectives in HIV PathogenesisHow to Define the Latent Reservoir: Tools of the TradeEpigenetic control of HIV-1 post integration latency: implications for therapyChallenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsImpact of Chromatin on HIV ReplicationManipulation of the host protein acetylation network by human immunodeficiency virus type 1HIV-1 functional cure: will the dream come true?Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchPerspectives for immunotherapy: which applications might achieve an HIV functional cure?Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsAchieving HIV-1 Control through RNA-Directed Gene RegulationReal-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIVLatency reversal and viral clearance to cure HIV-1.Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations.Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle SanctuaryHigh-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assemblyA Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.Progress towards an HIV cure: update from the 2014 International AIDS Society SymposiumEx vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoModeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.Integrated and Total HIV-1 DNA Predict Ex Vivo Viral OutgrowthLeveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsHuman Galectin-9 Is a Potent Mediator of HIV Transcription and ReactivationEx Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
P2860
Q26747110-E2AC06C8-B295-4D25-A7B7-73BA682AA9CEQ26766705-8FED5766-1C42-4DA2-BF46-5CD2225B5186Q26781191-46D0E11C-ED21-4669-93FA-C98B48A5D9CFQ26781511-9C2F9347-245F-4633-93AE-048CF69F5ADFQ26782046-9BEF0FCA-13D7-4E92-B762-1574F5D08E62Q26795463-E6B7EA2D-CBE1-4196-89FA-820E5938D817Q26865803-C16F82CB-B775-4C04-BD71-D28CC9B6F195Q28077662-02827525-9336-461E-98A3-8D821ACBD1B2Q28078726-5D85EC9E-A0D8-4C23-9993-C11F27976EA9Q28079455-FFEAAF98-EFB2-4A80-9BF1-A7784D24FE7FQ28080090-C410F3F0-E2F8-4CA9-AE47-D1C1F3BE9B10Q28551642-630A86DF-F37C-48A0-A72C-2A3E1F326298Q30248766-5747213D-D2F4-4D5F-BA12-9A81139FC6C3Q30490742-4234C76A-9648-4B7D-8E5C-B553A9A21062Q33654409-1ACB4348-78E9-4D62-B57A-0C5A0655E400Q33742139-22ED3608-6A58-426E-9F86-D648B8C947D9Q33817708-1F252C7E-C72E-48CA-86A8-A41C4B1BA0E4Q33893725-6B9C1572-44A2-4D49-B3BB-29F5E5435ACEQ33911247-179821CB-8866-4D41-9503-3A1085BB5377Q34869380-CE2CC017-6F10-4D06-B2CE-388CC7B84C80Q35436367-6B03F292-6C40-41A0-944C-10DB5713CE39Q35680431-4C1AC4A2-2DC2-42AD-BF52-F83A2B0CFE84Q35720063-4FD00BC4-8B52-4027-9EDC-AA558A728C5CQ35778783-113AC635-15D8-418F-A6C0-17CF8F8381D2Q35819184-BB5ED3A5-8DA5-4EF3-A2C1-7C107BD25071Q35822484-4034683A-496A-42FB-BC5D-42F5474A0DD8Q35833324-C923631D-35B5-4CA1-ADD0-B6DA7F50B79AQ35914266-F8F74B89-5BD5-4725-8247-7ABBB816E474Q35944804-B230D773-25FD-44A1-A802-5533FEF1F12DQ36030989-84BFF508-64D5-4DB3-B3C7-27E70F0DADF1Q36037844-0A3EE158-1174-4D58-9F2E-9C7DDA5462C1Q36076018-520B244F-856D-4A72-9A13-3269CD3D6E49Q36086345-DE72C954-A9F3-448F-8049-FB60C076ECD9Q36104946-B5A7433F-5A81-4213-B04E-A9E2D4D1DC58Q36113077-1B068705-85CB-4941-B07F-F6BBEAACF696Q36121883-7BE17EF7-E1A6-4408-983C-01261B742195Q36311695-07ED9BC3-499C-4323-A3A6-71AC14EA6318Q36361960-C129012E-FAF7-4EB4-888E-F6A537E8B3E8Q36481572-F8B3359F-4CBD-4EE5-A44F-296DBF1C6D8AQ36515149-46A2C496-B46D-4FBB-B4FC-BC90ACBE3431
P2860
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Panobinostat, a histone deacet ...... single group, clinical trial.
@en
type
label
Panobinostat, a histone deacet ...... single group, clinical trial.
@en
prefLabel
Panobinostat, a histone deacet ...... single group, clinical trial.
@en
P2093
P50
P921
P1433
P1476
Panobinostat, a histone deacet ...... single group, clinical trial.
@en
P2093
Ajantha Solomon
Anni Winckelmann
Christel R Brinkmann
Christian Erikstrup
Maria Buzon
Mathias Lichterfeld
Sarah Palmer
P304
P356
10.1016/S2352-3018(14)70014-1
P50
P577
2014-09-15T00:00:00Z